- $137.40m
- $131.64m
Brief: Enlivex Announces Issuance Of New European Patent
U.S. STOCKS ON THE MOVE-Hallador Energy, Washington Prime Group, Abbott Labs
Enlivex: Jumps on Canadian patent for potential COVID-19 treatment
Brief: Enlivex Announces Issuance Of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods And Uses Of Allocetra Immunotherapy
Brief: Enlivex Announces Research Collaboration With Yale Cancer Center
Brief: Enlivex Receives Notice Of Allowance For Japanese Patent Application Covering The Use Of Allocetra In Combination With Car-T Therapies
Brief: Enlivex And Mount Sinai Health System Announce Research Collaboration For The Development Of Allocetra In Combination With Immune Checkpoint Inhibitors
Brief: Enlivex Receives Notice Of Allowance For Chinese Patent Application Covering Allocetra Immunotherapy
Brief: Enlivex Announces Issuance Of New U.S. Patent Covering Methods Of Treating Gout, Inflammatory Bowel Disease, Crohn’S Disease, Ulcerative Colitis And GvHD Using Allocetra Immunotherapy
Enlivex: Down on upsized bought deal offering
Brief: Enlivex Increases Previously Announced Bought Deal Offering To Approximately $46.0 Mln Of Ordinary Shares
Brief: Enlivex Therapeutics Files Prospectus Supplement Related To Offering Of Ordinary Shares - SEC Filing
Enlivex: Jumps on positive data from experimental COVID-19 therapy study
Brief: Enlivex Therapeutics Announces Issuance Of New Chinese Patent Covering Allocetra Immunotherapy
Enlivex: Surges on positive early data from experimental COVID-19 therapy study
Brief: Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
Brief: Enlivex Therapeutics Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient With Erosive Osteoarthritis Treated With Allocetra
Brief: Enlivex Therapeutics Says Phase IIb Trial In Sepsis Patients Remains On Track For Initiation In Q4 2020
U.S. STOCKS ON THE MOVE-McDonald's, New York Times, Pfizer, JPM